MA-CLS-2 Cells
General information
Description | The MA-CLS-2 cell line was established from the pleural effusion of a 47 year-old female in 1998. pT1 NO GII. |
---|---|
Organism | Human |
Tissue | Breast |
Disease | Ductal carcinoma |
Metastatic site | Pleural effusion |
Synonyms | MACLS-2, MACLS2 |
Characteristics
Age | 47 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Monolayer, adherent |
Identifiers / Biosafety / Citation
Citation | MA-CLS-2 (Cytion catalog number 300271) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Tumorigenic | Yes, in nude mice |
---|---|
Ploidy status | Aneuploid |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:2 to 1:4 is recommended |
Seeding density | 2 x 10^4 cells/cm^2 |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | Fast |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
CSF1PO: 11
D13S317: 11
D16S539: 11
D5S818: 11
D7S820: 8,9
TH01: 7
TPOX: 8
vWA: 17,18
D3S1358: 14,18
D21S11: 29
D18S51: 15
Penta E: 13
Penta D: 9,13
D8S1179: 13
FGA: 24
|
HLA alleles |
A*: 24:02:01, 29:02:01
B*: 18:01:01, 51:08:01
C*: 12:03:01, 16:02:01
DRB1*: 03:132, 04:03:01
DQA1*: 03:01:01, 05:01:01
DQB1*: 02:01:01, 03:02:01
DPB1*: 04:01:01
E: 01:01:01, 01:03:02
|